Clinical trials: Community Acquired Pneumonia (CAP)
Tracheitis, Tracheobronchitis
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
This post-marketing observational study (PMOS) will be conducted in a prospective, single-arm, single-country, multicenter format.
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01130883
- Where
- 135 sites in Czechia
- Volunteers
- 3,130 people
- Sponsor
- Abbott
Community Acquired Pneumonia
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
The aim of this study is to test if BPS (Bacterial Pneumonia Score) guided antibiotic use in children with non severe community acquired pneumonia (CAP) and pneumoccocal vaccine will reduce antibiotic use as compared to standard…
- Trial name
- NCT01875731
- Testing
- BPS, Guideline
- Where
- Argentina
- Volunteers
- 66 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Community Acquired Pneumonia (CAP)
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.
- Trial name
- NCT04613375
- Testing
- Urine sample collection, Saliva collection
- Where
- 5 sites in Spain
- Volunteers
- 1,821 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
- Trial name
- LEAP2 (NCT02813694)
- Testing
- lefamulin, Moxifloxacin
- Where
- 155 sites in United States, Argentina and 18 more
- Volunteers
- 738 people
- Sponsor
- Nabriva Therapeutics AG
Community Acquired Respiratory Disease Syndrome
Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
The goal of the study is to determine whether providing early treatment with a glucocorticoid drug, called methylprednisolone, will improve survival in critically ill patients with severe community-acquired pneumonia (CAP).
- Trial name
- ESCAPe (NCT01283009)
- Testing
- Inactive Substance, Methylprednisolone
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 584 people
- Sponsor
- VA Office of Research and Development
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336505
- Testing
- Cethromycin, Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 584 people
- Sponsor
- Advanced Life Sciences, Inc.
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Community Acquired Pneumonia, Severe
Ticagrelor in Severe Community Acquired Pneumonia
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia.
- Trial name
- TCAP (NCT01998399)
- Testing
- Ticagrelor
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gordon Bernard
Community Acquired Pneumonia (CAP)
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community…
- Trial name
- NCT00809328
- Testing
- Azithromycin
- Where
- 34 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Pfizer
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Coccidioidomycosis
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
This is a Phase IV randomized, double-blinded, placebo-controlled study in 1000 individuals aged 18 years or older, with community acquired pneumonia (CAP) who meet all eligibility criteria in endemic regions.
- Trial name
- NCT02663674
- Testing
- Fluconazole
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Bacterial
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.
- Trial name
- NCT01189487
- Testing
- ampicillin sodium/sulbactam sodium
- Where
- 22 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Pfizer
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Infectious Pneumonia, Severe COVID-19
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Primary objective: To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
- Trial name
- NCT05254990
- Testing
- Reparixin
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 414 people
- Sponsor
- Dompé Farmaceutici S.p.A
Pneumonia, Community-Acquired Infections
Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO
The purpose of this study is to compare the efficacy of CPAP application by a helmet and O2 administration by a Venturi mask in terms of gas exchanges improvement in patients with acute respiratory failure due to…
- Conditions
- Pneumonia, Community-Acquired Infections, Respiratory Insufficiency, Acute Lung Injury
- Trial name
- CAPOVeRSO (NCT00603564)
- Testing
- Castar Starmed (CPAP) delivered by a helmet
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- University of Milan
Lower Respiratory Tract Infection (LRTI)
Procalcitonin Antibiotic Consensus Trial (ProACT)
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory…
- Trial name
- ProACT (NCT02130986)
- Testing
- Procalcitonin level, Results of procalcitonin (PCT) level to treating clinician, Provide procalcitonin guideline to treating clinician
- Where
- 13 sites in United States
- Volunteers
- 1,664 people
- Sponsor
- University of Pittsburgh
Pneumonia
Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical trial will test the effectiveness of short (5-day) vs.standard (10-day) course therapy in children who are diagnosed with CAP and…
- Trial name
- NCT02891915
- Testing
- Amoxicillin, Amoxicillin-clavulanate, Cefdinir
- Where
- 9 sites in United States
- Volunteers
- 385 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Bacterial
A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.
- Trial name
- NCT00797108
- Testing
- sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 35 people
- Sponsor
- Pfizer
Community-Acquired Pneumonia (CAP)
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).
- Trial name
- NCT00640926
- Testing
- Radezolid
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 158 people
- Sponsor
- Melinta Therapeutics, Inc.